Characteristics of monogenic inflammatory bowel disease in very early-onset cases: a Japanese multicenter registry study

Natsuki Ito; Takahiro Kudo; Keisuke Jimbo; Ryusuke Nambu; Fumihiko Kakuta; Tatsuki Mizuochi; Takeshi Saito; Shin-ichiro Hagiwara; Naomi Iwata; Nao Tachibana; Hideki Kumagai; Takashi Ishige; Toshifumi Yodoshi; Mikihiro Inoue; Shigeo Nishimata; Hitoshi Tajiri; Eitaro Hiejima; Mika Sasaki; Sawako Kato; Hirotaka Shimizu; Yuri Hirano; Toshiaki Shimizu; Katsuhiro Arai; Japanese Pediatric Inflammatory Bowel Disease Registry (JPIBD-R)

doi:10.5217/ir.2025.00203

Articles

Page Path: HOME > Intest Res > Ahead-of print articles > Article

Original Article Characteristics of monogenic inflammatory bowel disease in very early-onset cases: a Japanese multicenter registry study: Natsuki Ito¹, Takahiro Kudo¹, Keisuke Jimbo¹, Ryusuke Nambu², Fumihiko Kakuta³, Tatsuki Mizuochi⁴, Takeshi Saito⁵, Shin-ichiro Hagiwara⁶, Naomi Iwata⁷, Nao Tachibana⁸, Hideki Kumagai⁹, Takashi Ishige¹⁰, Toshifumi Yodoshi¹¹, Mikihiro Inoue¹², Shigeo Nishimata¹³, Hitoshi Tajiri¹⁴, Eitaro Hiejima¹⁵, Mika Sasaki¹⁶, Sawako Kato¹⁷, Hirotaka Shimizu¹⁸, Yuri Hirano¹⁸, Toshiaki Shimizu¹, Katsuhiro Arai¹⁸, Japanese Pediatric Inflammatory Bowel Disease Registry (JPIBD-R); DOI: https://doi.org/10.5217/ir.2025.00203
Published online: February 24, 2026

¹Department of Pediatrics, Faculty of Medicine, Juntendo University, Tokyo, Japan

²Division of Gastroenterology and Hepatology, Saitama Children’s Medical Center, Saitama, Japan

³Department of General Pediatrics and Gastroenterology, Miyagi Children’s Hospital, Miyagi, Japan

⁴Department of Pediatrics and Child Health, Kurume University School of Medicine, Fukuoka, Japan

⁵Division of Pediatric Surgery, Chiba Children’s Hospital, Chiba, Japan

⁶Department of Gastroenterology, Nutrition and Endocrinology, Osaka Women’s and Children’s Hospital, Osaka, Japan

⁷Department of Infection and Immunology, Aichi Children’s Health and Medical Center, Aichi, Japan

⁸Department of Gastroenterology, Tokyo Metropolitan Children’s Medical Center, Tokyo, Japan

⁹Department of Pediatrics, Jichi Medical University, Tochigi, Japan

¹⁰Department of Pediatrics, Gunma University Graduate School of Medicine, Gunma, Japan

¹¹Department of Pediatrics, Okinawa Chubu Hospital, Okinawa, Japan

¹²Department of Pediatric Surgery, Fujita Health University, Aichi, Japan

¹³Department of Pediatrics and Adolescent Medicine, Tokyo Medical University, Tokyo, Japan

¹⁴Department of Pediatrics, Osaka General Medical Center, Osaka, Japan

¹⁵Department of Pediatrics, Kyoto University Hospital, Kyoto, Japan

¹⁶Department of Pediatrics, National Hospital Organization Morioka Medical Center, Iwate, Japan

¹⁷Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan

¹⁸Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan

Correspondence to Takahiro Kudo, Department of Pediatrics, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. E-mail: t-kudo@juntendo.ac.jp

• Received: September 1, 2025 • Revised: December 3, 2025 • Accepted: December 22, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

1,805 Views
87 Download

Full Article

Download PDF

Abstract
Graphical abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
REFERENCES

Abstract

Background/Aims
Very early-onset inflammatory bowel disease (VEO-IBD), defined as IBD diagnosed before 6 years of age, is highly influenced by genetic factors. Monogenic IBD is a type of enterocolitis caused by a single pathogenic variant. However, information on Asian patients with VEO-IBD and monogenic IBD is limited. This study investigated real-world data on VEO-IBD and monogenic IBD in Japan.
Methods
We evaluated patients with VEO-IBD registered in the Japanese Pediatric Inflammatory Bowel Disease Registry, a multicenter prospective registry study conducted between 2012 and 2021. We categorized patients into monogenic and non-monogenic IBD groups and compared their clinical characteristics and outcomes.
Results
Among 703 pediatric patients with IBD, 68 (9.7%) had VEO-IBD. Of these, 26 (38.2%) had ulcerative colitis, 16 (23.5%) had Crohn’s disease, 23 (33.8%) had unclassified IBD (IBD-U), and 3 (4.4%) had Behçet’s disease. Genetic testing was performed in 25 patients (36.8%), and monogenic IBD was identified in 5 of the 23 patients with IBD-U (7.4% of the VEO-IBD cohort). All 5 monogenic cases presented with an IBD-U phenotype. Monogenic IBD included A20 haploinsufficiency, interleukin-10 receptor subunit alpha deficiency, chronic granulomatous disease, Wiskott–Aldrich syndrome, and Hermansky–Pudlak syndrome. Monogenic IBD was significantly associated with IBD-U phenotype (P=0.015) and severe infections before 1 year of age (P=0.004).
Conclusions
Patients with VEO-IBD who present an IBD-U phenotype and have a history of severe infections during infancy should be prioritized for genetic analysis to investigate the possibility of monogenic IBD.
Keywords: Inflammatory bowel diseases; Pediatric Crohn’s disease; Pediatric ulcerative colitis; Genetic testing; Registries

Graphical abstract

INTRODUCTION

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic conditions that cause recurrent inflammation of the digestive tract. IBD arises from the interactions between environmental factors, the immune system, changes in the gut microbiome, and genetic factors. Because of its complex management, this disease poses significant challenges in pediatric healthcare.

Very early-onset IBD (VEO-IBD), defined as IBD diagnosed before 6 years of age, accounts for approximately 5% to 15% of pediatric IBD cases, with its prevalence varying across studies and populations [1,2]. This subgroup has drawn attention to the potential genetic backgrounds, especially with monogenic IBD, which is caused by a single pathogenic variant [3,4]. Pathogenic variants often relate to innate immune dysfunctions, such as T and B cell functional abnormalities, heightened inflammation, autoinflammatory disorders, or epithelial barrier dysfunctions [5]. Due to these varieties, monogenic IBD may not be classifiable by standard clinical, endoscopic, or histological characteristics. They most often present with unique features such as severe disease progression and refractoriness to conventional treatments. However, patients refractory to conventional treatments may respond to bone marrow transplantation or targeted molecular therapies, highlighting the importance of the early detection of underlying inborn errors of immunity or genetic anomalies [6].

Despite the identification of more than 80 causative genes for monogenic IBD through global genetic research, specific genetic backgrounds and their implications for disease management in Asia have been underreported [7,8]. VEO-IBD is a heterogeneous group of diseases, and elucidating the clinical characteristics and disease progression across different regions and ethnicities could improve clinical understanding of the disease [9]. Therefore, this study aimed to understand the clinical characteristics of VEO-IBD in non-monogenic and monogenic Japanese patients.

METHODS

1. The Japanese Pediatric Inflammatory Bowel Disease Registry

The design and eligibility criteria of the Japanese Pediatric Inflammatory Bowel Disease Registry (JPIBD-R) have been detailed in a previous article [10]. Briefly, the JPIBD-R is an electronic registry established to prospectively enroll Japanese pediatric patients with IBD from 2012 to 2021. It aims to comprehensively assess the pretreatment history, clinical features, tests and treatments, treatment responses, and outcomes. Twenty-two facilities specializing in pediatric IBD in Japan participated in this registry, enrolling 703 patients electronically. Each facility registered patients who were diagnosed according to the revised Porto criteria [11]. A standardized dataset was collected at diagnosis and updated every 6 months with follow-up data until the end of the study.

2. Study Design and Definitions

This was a prospective registry study of all patients with IBD registered between October 1, 2012, and December 31, 2019. Follow-up data were collected until March 31, 2021. Data of all the patients considered in this study were obtained from the JPIBD-R. Pediatric patients who were diagnosed with IBD before 6 years of age (VEO-IBD) and were registered in the JPIBD-R were included in this analysis. Descriptive comparisons were performed between the monogenic and non-monogenic IBD groups. The diagnosis of IBD was based on the revised Porto criteria, and the Paris classification was used to characterize the disease phenotype at diagnosis [11,12]. Monogenic IBD was defined as IBD associated with known genetic variants that affect primary immune deficiencies, epithelial barrier defects, or other related factors. Extraintestinal manifestations were defined as classical inflammatory manifestations pathophysiologically associated with IBD, including oral ulcers, arthritis, uveitis, and folliculitis. Remission was assessed at each patient’s final follow-up visit and defined as sustained clinical remission while receiving maintenance medical therapy. Curative outcomes were defined as the complete absence of clinical and endoscopic disease activity following hematopoietic stem cell transplantation (HSCT).

3. Statistical Analysis

Discrete variables were compared using Fisher exact test, and continuous variables were compared using Student t-test. Because multivariate logistic regression was not performed due to the small number of monogenic IBD cases, only univariate analyses were conducted. Statistical analyses and figure generation were performed using GraphPad Prism version 9.0 (GraphPad Software, San Diego, CA, USA).

4. Statement of Ethics

This study protocol was reviewed and approved by the Ethics Committee of Juntendo University (approval number 13-085). Informed consent was obtained from all parents or caregivers, and written informed consent was obtained from the parent or legal guardian of all participants prior to the study. Additionally, written informed consent for the publication of identifying details (such as age, gender, and illness) was obtained from the parent or legal guardian of each participant.

RESULTS

1. Patient Characteristics and Genetic Analysis

During the observation period, among 703 pediatric IBD patients in the registry, 68 (9.7%) had VEO-IBD. Of these, 26 (38.2%) were diagnosed with UC, 16 (23.5%) with CD, 23 (33.8%) with unclassified IBD (IBD-U), and 3 (4.4%) with Behçet’s disease. Genetic testing was performed in 25 patients (36.8% of the VEO-IBD cohort), resulting in genetic diagnoses in 6 cases (8.8%). Monogenic IBD was identified in 5 of the 23 patients with IBD-U (7.4% of the overall cohort). Notably, all 5 monogenic IBD cases exhibited an IBD-U phenotype at presentation, and none were initially classified as typical UC or CD. In addition, 1 patient with Behçet’s disease was found to have trisomy 8 on genetic analysis; this case was not classified as monogenic IBD. Twenty-five patients (36.8%) underwent genetic testing, and because some patients received more than one test, a total of 26 tests were performed. The modalities included targeted gene panel sequencing in 11 patients, whole-exome sequencing in 10, whole genome sequencing in 2, and disease-specific Sanger sequencing in 3 patients. Among the 68 patients with VEO-IBD, the median follow-up duration was 5.6 years. At diagnosis, growth failure (defined as height Z-score <–2 standard deviation) was present in 23.5% of the cohort (16 out of 68 patients). An additional 8 patients developed new-onset growth failure during the follow-up period (median 5.6 years). Specifically, 6 of these patients developed growth failure within 6 months of diagnosis, 1 patient at 12 months, and 1 patient at 24 months post-diagnosis. In total, 24 patients (35.3%) experienced growth failure at or during follow-up. The median ages at symptom onset and diagnosis were 22 months and 34 months, respectively, and 42.6% of patients were male. The clinical phenotypes and genetic findings of the cohort are summarized in Table 1.

2. Clinical Characteristics of Monogenic IBD

The clinical profiles of the patients diagnosed with monogenic IBD are described in Tables 2 and 3. The predominant clinical manifestations were diarrhea, growth failure, and perianal disease, each observed in 3 cases (60%). Disease phenotyping revealed IBD-U in all 5 cases (100%), severe disease (characterized by a mean Pediatric Ulcerative Colitis Activity Index >65 and Pediatric Crohn’s Disease Activity Index >40) in 2 (40%), and small intestinal lesions in 3 (60%). A notable history of severe infections before 1 year of age, indicative of systemic symptoms attributable to immune dysregulation, was observed in 3 cases (60%). No fatalities occurred during the median follow-up period. Various therapeutic interventions led to remission in all patients with monogenic IBD. HSCT has been curative for patients with interleukin-10 receptor subunit alpha (IL-10RA) deficiency, chronic granulomatous disease, and Wiskott–Aldrich syndrome. Patients with A20 haploinsufficiency and Hermansky–Pudlak syndrome show sustained remission with immunosuppressive agents and biologics.

3. Clinical Features and Treatment in Monogenic versus Non-Monogenic IBD

Tables 3 and 4 summarize the phenotypic comparisons between monogenic and non-monogenic IBD. Since genetic testing was not performed for all patients clinically classified as non-monogenic IBD, only those who underwent genetic evaluation were included in the comparison—5 patients with monogenic IBD and 20 patients without pathogenic variants. The onset of monogenic IBD was earlier (17.6 months) than was non-monogenic IBD (24.3 months), although this difference was not statistically significant (P=0.563). Additionally, a higher percentage of males was observed in the monogenic IBD group (80.0%) than in the non-monogenic IBD group (30.0%) (P=0.121). The follow-up duration did not differ significantly between the 2 groups (monogenic IBD: 30.6 ± 18.29 months; non-monogenic IBD: 48.55 ± 30.02 months; P=0.277). Phenotypically, all monogenic IBD cases were significantly more frequently classified as IBD-U (P=0.015), in contrast to the balanced distribution of CD, UC, and IBD-U observed in non-monogenic IBD. Regarding lesion distribution, non-monogenic IBD predominantly presented with CD as isolated colitis (L2, 56.2%), with upper gastrointestinal lesions observed as L4a (37.5%) and L4b (25.0%), and perianal disease in 25.0% of the cases. UC cases commonly presented with pancolitis (E4, 84.6%). Although perianal disease was more frequent in monogenic IBD (60.0%) than in non-monogenic IBD (20.0%), the difference was not statistically significant (P=0.113). The prevalence of severe disease at diagnosis was higher in patients with monogenic IBD (40.0%) than in those with non-monogenic IBD (30.0%) (P=1.000). At diagnosis, patients with monogenic IBD tended to have lower mean Z-scores for both weight (–2.2) and height (–2.5) compared with those with non-monogenic IBD (–1.2 for weight and –1.4 for height). However, these differences did not reach statistical significance (weight: P=0.074; height: P=0.080). A history of severe infections before 1 year of age was significantly more common in the monogenic IBD group (60.0%) than in the non-monogenic IBD group (0%) (P=0.004). A family history of IBD was reported in 20.0% of the monogenic IBD cases versus 15.0% of the non-monogenic IBD cases (P=1.000). Milk allergies were reported more frequently in patients with monogenic IBD (20.0%) than in those with non-monogenic IBD (5.0%) (P=0.367). The remission maintenance rates achieved through drug therapy, including biologics, were 40.0% and 40.0% for non-monogenic and monogenic IBD, respectively (P=1.000). Steroids were administered to 80.0% of the patients with monogenic IBD and 85.0% of the patients with non-monogenic IBD (P=1.000). Biologics were used in 20.0% of patients with monogenic IBD and 60.0% of patients with non-monogenic IBD (P=0.160). In the monogenic IBD group, only 1 patient was treated with infliximab. Various biologics have been used to treat non-monogenic IBD, including infliximab, adalimumab, ustekinumab, golimumab, and vedolizumab. Tumor necrosis factor failure was observed in 5 cases (25.0%) of non-monogenic IBD, leading to the use of subsequent biological therapies. Surgical interventions were reported in 10.0% of non-monogenic IBD cases, but not in monogenic IBD cases. HSCT was performed in 3 cases (60.0%) of monogenic IBD, all of which achieved a curative outcome. No fatalities were reported in either group. Given the very small number of monogenic IBD cases (n=5) and the presence of complete separation in some variables, multivariate logistic regression was not performed. Therefore, we presented only univariate analyses.

Among the 68 patients with VEO-IBD, genetic testing was performed in 25 (36.8%). As expected, patients selected for genetic testing tended to have more severe clinical features, including a higher frequency of growth failure, perianal lesions, and severe disease activity.

DISCUSSION

This study investigated the clinical and genetic features of VEO-IBD and monogenic IBD in Japanese children. The results highlight the significant role of genetic factors in the onset and progression of these conditions. Based on our findings, a genetically guided approach to diagnosis and treatment may improve clinical outcomes in pediatric IBD. Early genetic screening could enable the use of more precise and potentially safer therapies compared to standard treatment options. The prevalence of VEO-IBD in our study (9.7%) was comparable to that reported by other institutions, which ranged from 2.9% to 13.9% [6,13]. Given that the prevalence of VEO-IBD in the pediatric population is significant, accurate diagnosis is essential. Although the proportions of UC and CD in VEO-IBD are comparable to those in older children, the incidence of IBD-U and monogenic IBD is higher [4]. Moreover, comparing monogenic and non-monogenic IBD cases offers insights into the clinical phenotype, providing a clearer understanding of the disease’s heterogeneity.

The initial major finding of our study was that the prevalence of genetic variants associated with monogenic IBD in the Japanese pediatric population diagnosed with VEO-IBD was comparable to the previously reported global average. The literature indicates that the prevalence of monogenic IBD in VEO-IBD cases ranges from <1% to >30% [7,14,15]. Our discovery that 7.4% of the VEO-IBD cohort was diagnosed with monogenic IBD aligns closely with the outcomes of cohort studies conducted in Canada and the United States. In Canada, whole-exome sequencing was performed on 1,005 pediatric IBD cases, of which 140 were diagnosed with VEO-IBD and 7.8%, with monogenic IBD [6]. Similarly, a U.S. cohort study involving 216 patients with VEO-IBD identified 17 patients (7.9%) with monogenic IBD [14].

Gene diagnosis plays a crucial role in determining the prognosis and treatment strategies for various genetic disorders. For conditions such as IL-10RA deficiency, chronic granulomatous disease, and Wiskott–Aldrich syndrome, bone marrow transplantation has proven to be a curative treatment [15-17]. Conversely, for disorders such as A20 haploinsufficiency and Hermansky–Pudlak syndrome, understanding the underlying pathogenesis markedly enhances treatment prospects [18,19]. The limited number of reported cases of monogenic IBD, totaling only 5, can be attributed to factors such as the registry-based nature of the study and the historically low rates of genetic testing in earlier years. Although genetic testing has advanced in Japan with the introduction of panels and diagnostic guidelines, many countries still lack access to these tests. Therefore, meticulous patient selection is essential.

The second important observation is that patients with monogenic IBD, compared to those with non-monogenic IBD, tend to have more IBD-U phenotype, and a history of severe infections before 1 year of age. This clinical course aligns with that presented in the literature, such as studies showing that patients with IL-10RA mutations, a common cause of monogenic IBD, are prone to serious perianal disease and early-onset severe infections [20]. A cohort study in India diagnosed 15 of 48 children with VEO-IBD (31%) as having monogenic IBD [21]. Compared to non-monogenic IBD, monogenic IBD was characterized by neonatal IBD, the presence of perianal disease, IBD-U, a history of consanguinity and sibling death, as well as wasting and stunting. In a cohort study from the U.S., compared to patients with non-monogenic IBD, those with monogenic IBD were diagnosed at a younger age and were more likely to experience CD phenotype with higher rates of stricturing and penetrating disease and extraintestinal manifestations [12]. Patients with monogenic IBD were also more likely to experience intensive care unit hospitalization, gastrostomy tube use, total parenteral nutrition use, stunting at the 3-year follow-up, HSCT, and death. These patients often require aggressive treatment strategies, including advanced biological therapies and, in some cases, surgical interventions. This finding is in line with those of previous studies that have documented the challenging management and prognosis of monogenic IBD owing to its aggressive nature. However, our study highlights the critical need for early and precise genetic diagnosis to guide the management of these patients effectively.

In this study, patients who underwent genetic testing showed higher rates of growth failure, perianal lesions, and severe disease; however, this pattern likely reflects the clinical tendency to test patients with more severe presentations rather than a true biological difference. Therefore, these findings should not be interpreted as evidence of phenotype–genotype associations. The European Society for Paediatric Gastroenterology Hepatology and Nutrition recommends genetic testing for all patients with infantile-onset IBD and consideration of testing for those with VEO-IBD [6]. Identifying an underlying monogenic cause can directly guide treatment strategies, including the potential use of targeted therapies or HSCT.

This study also offers several novel contributions. First, it is one of the largest multicenter, registry-based analyses of VEO-IBD and monogenic IBD in Japanese children, conducted in a context where comprehensive genetic testing is still relatively uncommon. Second, our findings highlight the relevance of ethnic and regional genetic differences. For example, IL-10RA mutations and other monogenic variants appear more frequently in East Asian populations [20], emphasizing the need for diagnostic and therapeutic approaches tailored to specific genetic backgrounds. Third, we quantitatively compared clinical features at diagnosis between patients with and without monogenic IBD. IBD-U phenotype and a history of severe infections before 1 year of age were significantly associated with monogenic IBD, suggesting that these features may be useful indicators for selecting candidates for genetic testing. Finally, our data reflect a temporal trend in genetic testing practices in Japan: while a previous national report indicated that only 26.9% of VEO-IBD cases had undergone genetic testing up to 2016 [11], our cohort showed a higher rate of 36.8%, suggesting increasing clinical recognition of its utility.

Although this study provides valuable insights into the genetic underpinnings of VEO-IBD, it has some limitations. First, genetic analysis was performed in only a portion of VEO-IBD cases, which may not fully represent the spectrum of genetic diversity within this population. Importantly, the absence of genetic testing does not exclude the possibility of monogenic IBD, and some patients who were not tested may still harbor monogenic etiologies. Second, given that the study involved multiple institutions and that not all diagnosed patients meeting the inclusion criteria were subjected to genetic analysis during the study period, there is a potential for selection bias. Third, our focus on the Japanese pediatric population may limit the generalizability of our findings to other ethnic groups, necessitating further studies in diverse populations. Fourth, the relatively small number of patients diagnosed with monogenic IBD may affect the generalizability of our findings. Future studies with larger cohorts will be necessary to validate and extend these observations. To address these limitations, we plan to perform additional genetic testing for patients with refractory disease among those who were not genetically analyzed, as this may uncover previously unrecognized monogenic cases. We are also considering an extended follow-up study with a larger cohort, which will help validate and expand upon our findings.

In conclusion, our multicenter analysis highlights that certain clinical features in VEO-IBD (IBD-U phenotype and early severe infections) should prompt early genetic evaluation for monogenic IBD, as timely identification of a monogenic etiology can critically inform optimal treatment (including curative therapies like HSCT) and improve patient outcomes.

NOTES

Funding Source

This work was partly supported by a Grant-in-Aid from the National Center for Child Health and Development (grant number 2019A-3) and a Health and Labour Science Research Grant for Research on Intractable Diseases from the Ministry of Health, Labour, and Welfare of Japan (grant number 26-067). The funders had no role in the design, data collection, data analysis, and reporting of this study.

Conflict of Interest

Arai K has received grant support from Nippon Kayaku Co., Ltd. and received consulting and lecture fees from Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., EA Pharma Co., Ltd., AbbVie GK, Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K. Mizuochi T received lecture fees from AbbVie GK, Takeda Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Eisai Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nobelpharma Co., Ltd., Sekisui Medical Co., Ltd., and Nippon Kayaku Co., Ltd., and consulting fees from AbbVie GK and Takeda Pharmaceutical Co., Ltd. Nambu R received speaker’s fees from AbbVie GK. and Mitsubishi Tanabe Pharma Corp. All other authors have no conflicts of interest to declare.

Data Availability Statement

All analyses relevant to the study are included in this manuscript. All data requests should be submitted to the corresponding authors for consideration.

Author Contributions

Conceptualization; Data curation; Formal analysis: Ito N, Kudo T, Arai K. Funding acquisition: Kudo T, Arai K. Investigation: all authors. Methodology: Ito N, Kudo T, Arai K. Project administration; Resources: Kudo T, Arai K. Software: Ito N. Supervision: Kudo T, Arai K. Validation; Visualization: Ito N, Kudo T, Arai K. Writing–original draft: Ito N, Kudo T, Arai K. Writing–review & editing: all authors. Approval of final manuscript: all authors.

Table 1.

VEO-IBD Phenotype and Genetic Analysis (n=68)

Variable	No. of patients (%)
Ulcerative colitis	26 (38.2)
Crohn’s disease	16 (23.5)
IBD unclassified	23 (33.8)
Behçet’s disease	3 (4.4)
Genetic diagnosis	5 (7.4)
A20 haploinsufficiency	1
IL-10RA deficiency	1
Chronic granulomatous disease	1
Wiskott–Aldrich syndrome	1
Hermansky–Pudlak syndrome	1
Genetic analysis	25 (36.8)
Targeted gene panel sequencing	11 (16.2)
Whole-exome sequencing	10 (14.7)
Whole genome sequencing	2 (2.9)
Disease-specific Sanger sequencing	3 (4.4)

One patient underwent 2 genetic testing modalities (a targeted gene panel followed by whole-exome sequencing), hence the total number of tests (n=26) is higher than the number of patients tested (n=25).

VEO-IBD, very early onset inflammatory bowel disease; IBD, inflammatory bowel disease; IL-10RA, interleukin-10 receptor subunit alpha.

Table 2.

Monogenic Inflammatory Bowel Disease

Syndrome	Sex	Age at onset (mo)	Diagnostic modality	Perianal disease	EIM	Treatment	Outcome
A20 haploinsufficiency	F	2	Whole-exome sequencing	Yes	Uveitis, arthritis, eczema	5-ASA, steroid, tacrolimus	Remission
IL-10RA deficiency	M	3	Targeted gene panel sequencing	Yes	Pneumonia and herpes infection	5-ASA, HSCT	Curative
Chronic granulomatous disease	M	35	Targeted gene panel sequencing	No	GBS infection	5-ASA, steroid, HSCT	Curative
Wiskott–Aldrich syndrome	M	43	Disease-specific Sanger sequencing (WAS)	Yes	Pneumonia, thrombocytopenia	Steroid, tacrolimus, cytapheresis, HSCT	Curative
Hermansky–Pudlak syndrome	M	6	Disease-specific Sanger sequencing (HPS1)	No	Ocular-cutaneous albinism	5-ASA, steroid, azathioprine, infliximab	Remission

EIM, extraintestinal manifestations; F, female; M, male; 5-ASA, 5-aminosalicylic acid; IL-10RA, interleukin-10 receptor subunit alpha; HSCT, hematopoietic stem cell transplantation; GBS infection, Group B Streptococcus infection.

Table 3.

IBD Phenotype in Monogenic versus Non-Monogenic Disease

	Monogenic (n=5)	Non-monogenic (n=20)	P-value
Age of onset (mo)	17.6 ± 17.7	24.3 ± 19.0	0.563
Infantile onset	3 (60.0)	11 (55.0)	1.000
Age of diagnosis (mo)	42.4 ± 43.1	32.7 ± 18.7	0.882
Male sex	4 (80.0)	6 (30.0)	0.121
Clinical features at onset
Diarrhea	3 (60.0)	17 (85.0)	0.252
Bloody stool	1 (20.0)	12 (60.0)	0.160
Vomiting	1 (20.0)	1 (5.0)	0.367
Perianal disease	3 (60.0)	4 (20.0)	0.113
≥ 1 Extraintestinal manifestations
Arthritis	1 (20.0)	1 (5.0)
Stomatitis	0	2 (10.0)
Uveitis	1 (20.0)	0
Folliculitis	0	1 (5.0)
Severe disease (PUCAI > 65, PCDAI > 40)	2 (40.0)	6 (30.0)	1.000
IBD-U	5 (100.0)	7 (35.0)	0.015
Small intestinal lesions	3 (60.0)	8 (40.0)	0.623
Height at diagnosis, Z-score	–2.5 ± 0.6	–1.4 ± 2.0	0.080
Weight at diagnosis, Z-score	–2.2 ± 0.8	–1.2 ± 1.3	0.074
Severe infections before 1 yr of age	3 (60.0)	0	0.004
Milk allergy	1 (20.0)	1 (5.0)	0.367
Family history (IBD)	1 (20.0)	3 (15.0)	1.000

Values are presented as mean±SD or number (%). Comparisons include only patients who underwent genetic testing (5 monogenic IBD; 20 non-monogenic IBD without pathogenic variants).

IBD, inflammatory bowel disease; PUCAI, Pediatric Ulcerative Colitis Activity Index; PCDAI, Pediatric Crohn’s Disease Activity Index; IBD-U, unclassified IBD; SD, standard deviation.

Table 4.

Comparison of Treatments between Monogenic and Non-Monogenic Diseases

Variable	Monogenic (n=5)	Non-monogenic (n=20)	P-value
5-ASA	4 (80.0)	18 (90.0)	0.504
Azathioprine/6-MP	1 (20.0)	10 (50.0)	0.341
Tacrolimus	2 (40.0)	5 (25.0)	0.597
Steroid (systemic)	4 (80.0)	17 (85.0)	1.000
Cytapheresis	1 (20.0)	0	0.200
Biologics	1 (20.0)	12 (60.0)^a	0.160
Infliximab	1 (20.0)	10 (50.0)
Adalimumab	0	4 (20.0)
Ustekinumab	0	6 (30.0)
Golimumab	0	0
Vedolizumab	0	2 (10.0)
Chinese medicine	0	1 (5.0)	1.000
Enteral nutrition	2 (40.0)	13 (65.0)	0.358
Total parenteral nutrition	2 (40.0)	8 (40.0)	0.590
Surgery	0	2 (10.0)	1.000
HSCT	3 (60.0)	0	0.004
Death	0	0
Good response to drug therapy: remission	2 (40.0)	8 (40.0)	1.000
Biologic 1st line	1 (20.0)	5 (25.0)	1.000
Biologic ≥2nd line	0	7 (35.0)	0.274
Anti-TNF failure	0	5 (25.0)	0.544

Values are presented as number (%).

^a Patients may have received multiple biological agents.

5-ASA, 5-aminosalicylic acid; 6-MP, 6-mercaptopurine; HSCT, hematopoietic stem cell transplantation; TNF, tumor necrosis factor.

REFERENCES

1. Benchimol EI, Mack DR, Nguyen GC, et al. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology 2014;147:803–813.Article PubMed
2. Crowley E, Muise A. Inflammatory bowel disease: what very early onset disease teaches us. Gastroenterol Clin North Am 2018;47:755–772.PubMed
3. Crowley E, Warner N, Pan J, et al. Prevalence and clinical features of inflammatory bowel diseases associated with monogenic variants, identified by whole-exome sequencing in 1000 children at a single center. Gastroenterology 2020;158:2208–2220.Article PubMed PMC
4. Lega S, Pin A, Arrigo S, et al. Diagnostic approach to monogenic inflammatory bowel disease in clinical practice: a ten-year multicentric experience. Inflamm Bowel Dis 2020;26:720–727.Article PubMed PDF
5. Ouahed J, Spencer E, Kotlarz D, et al. Very early onset inflammatory bowel disease: a clinical approach with a focus on the role of genetics and underlying immune deficiencies. Inflamm Bowel Dis 2020;26:820–842.Article PubMed PMC PDF
6. Uhlig HH, Charbit-Henrion F, Kotlarz D, et al. Clinical genomics for the diagnosis of monogenic forms of inflammatory bowel disease: a position paper from the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2021;72:456–473.Article PubMed PMC
7. Nambu R, Warner N, Mulder DJ, et al. A systematic review of monogenic inflammatory bowel disease. Clin Gastroenterol Hepatol 2022;20:e653–e663.Article PubMed
8. Kudo T, Arai K, Uchida K, et al. Very early-onset inflammatory bowel disease in Japan: a nationwide survey. J Gastroenterol Hepatol 2021;36:151–155.Article PubMed PDF
9. Kelsen JR, Conrad MA, Dawany N, et al. The unique disease course of children with very early onset-inflammatory bowel disease. Inflamm Bowel Dis 2020;26:909–918.Article PubMed PMC PDF
10. Nambu R, Arai K, Kudo T, et al. Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study. J Gastroenterol 2023;58:472–480.Article PubMed PDF
11. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;58:795–806.Article PubMed
12. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314–1321.PubMed
13. Bequet E, Sarter H, Fumery M, et al. Incidence and phenotype at diagnosis of very-early-onset compared with later-onset paediatric inflammatory bowel disease: a population-based study [1988-2011]. J Crohns Colitis 2017;11:519–526.Article PubMed
14. Collen LV, Kim DY, Field M, et al. Clinical phenotypes and outcomes in monogenic versus non-monogenic very early onset inflammatory bowel disease. J Crohns Colitis 2022;16:1380–1396.Article PubMed PMC PDF
15. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012;143:347–355.Article PubMed
16. Foroozonfar N, Hobbs JR, Hugh-Jones K, et al. Bone-marrow transplant from an unrelated donor for chronic granulomatous disease. Lancet 1977;1:210–213.PubMed
17. Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006;117:725–739.Article PubMed
18. Zhou Q, Wang H, Schwartz DM, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 2016;48:67–73.PubMed
19. Wei AH, Li W. Hermansky-Pudlak syndrome: pigmentary and non-pigmentary defects and their pathogenesis. Pigment Cell Melanoma Res 2013;26:176–192.Article PubMed
20. Zheng C, Huang Y, Hu W, et al. Phenotypic characterization of very early-onset inflammatory bowel disease with interleukin-10 signaling deficiency: based on a large cohort study. Inflamm Bowel Dis 2019;25:756–766.Article PubMed
21. Poddar U, Aggarwal A, Jayalakshmi K, et al. Higher prevalence of monogenic cause among very early onset inflammatory bowel disease in children: experience from a tertiary care center from Northern India. Inflamm Bowel Dis 2023;29:1572–1578.Article PubMed PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Characteristics of monogenic inflammatory bowel disease in very early-onset cases: a Japanese multicenter registry study

DOI: https://doi.org/10.5217/ir.2025.00203

XML Download

Figure

Characteristics of monogenic inflammatory bowel disease in very early-onset cases: a Japanese multicenter registry study

Graphical abstract

Graphical abstract

Characteristics of monogenic inflammatory bowel disease in very early-onset cases: a Japanese multicenter registry study

Variable	No. of patients (%)
Ulcerative colitis	26 (38.2)
Crohn’s disease	16 (23.5)
IBD unclassified	23 (33.8)
Behçet’s disease	3 (4.4)
Genetic diagnosis	5 (7.4)
A20 haploinsufficiency	1
IL-10RA deficiency	1
Chronic granulomatous disease	1
Wiskott–Aldrich syndrome	1
Hermansky–Pudlak syndrome	1
Genetic analysis	25 (36.8)
Targeted gene panel sequencing	11 (16.2)
Whole-exome sequencing	10 (14.7)
Whole genome sequencing	2 (2.9)
Disease-specific Sanger sequencing	3 (4.4)

Syndrome	Sex	Age at onset (mo)	Diagnostic modality	Perianal disease	EIM	Treatment	Outcome
A20 haploinsufficiency	F	2	Whole-exome sequencing	Yes	Uveitis, arthritis, eczema	5-ASA, steroid, tacrolimus	Remission
IL-10RA deficiency	M	3	Targeted gene panel sequencing	Yes	Pneumonia and herpes infection	5-ASA, HSCT	Curative
Chronic granulomatous disease	M	35	Targeted gene panel sequencing	No	GBS infection	5-ASA, steroid, HSCT	Curative
Wiskott–Aldrich syndrome	M	43	Disease-specific Sanger sequencing (WAS)	Yes	Pneumonia, thrombocytopenia	Steroid, tacrolimus, cytapheresis, HSCT	Curative
Hermansky–Pudlak syndrome	M	6	Disease-specific Sanger sequencing (HPS1)	No	Ocular-cutaneous albinism	5-ASA, steroid, azathioprine, infliximab	Remission

	Monogenic (n=5)	Non-monogenic (n=20)	P-value
Age of onset (mo)	17.6 ± 17.7	24.3 ± 19.0	0.563
Infantile onset	3 (60.0)	11 (55.0)	1.000
Age of diagnosis (mo)	42.4 ± 43.1	32.7 ± 18.7	0.882
Male sex	4 (80.0)	6 (30.0)	0.121
Clinical features at onset
Diarrhea	3 (60.0)	17 (85.0)	0.252
Bloody stool	1 (20.0)	12 (60.0)	0.160
Vomiting	1 (20.0)	1 (5.0)	0.367
Perianal disease	3 (60.0)	4 (20.0)	0.113
≥ 1 Extraintestinal manifestations
Arthritis	1 (20.0)	1 (5.0)
Stomatitis	0	2 (10.0)
Uveitis	1 (20.0)	0
Folliculitis	0	1 (5.0)
Severe disease (PUCAI > 65, PCDAI > 40)	2 (40.0)	6 (30.0)	1.000
IBD-U	5 (100.0)	7 (35.0)	0.015
Small intestinal lesions	3 (60.0)	8 (40.0)	0.623
Height at diagnosis, Z-score	–2.5 ± 0.6	–1.4 ± 2.0	0.080
Weight at diagnosis, Z-score	–2.2 ± 0.8	–1.2 ± 1.3	0.074
Severe infections before 1 yr of age	3 (60.0)	0	0.004
Milk allergy	1 (20.0)	1 (5.0)	0.367
Family history (IBD)	1 (20.0)	3 (15.0)	1.000

Variable	Monogenic (n=5)	Non-monogenic (n=20)	P-value
5-ASA	4 (80.0)	18 (90.0)	0.504
Azathioprine/6-MP	1 (20.0)	10 (50.0)	0.341
Tacrolimus	2 (40.0)	5 (25.0)	0.597
Steroid (systemic)	4 (80.0)	17 (85.0)	1.000
Cytapheresis	1 (20.0)	0	0.200
Biologics	1 (20.0)	12 (60.0)^a	0.160
Infliximab	1 (20.0)	10 (50.0)
Adalimumab	0	4 (20.0)
Ustekinumab	0	6 (30.0)
Golimumab	0	0
Vedolizumab	0	2 (10.0)
Chinese medicine	0	1 (5.0)	1.000
Enteral nutrition	2 (40.0)	13 (65.0)	0.358
Total parenteral nutrition	2 (40.0)	8 (40.0)	0.590
Surgery	0	2 (10.0)	1.000
HSCT	3 (60.0)	0	0.004
Death	0	0
Good response to drug therapy: remission	2 (40.0)	8 (40.0)	1.000
Biologic 1st line	1 (20.0)	5 (25.0)	1.000
Biologic ≥2nd line	0	7 (35.0)	0.274
Anti-TNF failure	0	5 (25.0)	0.544

Table 1. VEO-IBD Phenotype and Genetic Analysis (n=68)

VEO-IBD, very early onset inflammatory bowel disease; IBD, inflammatory bowel disease; IL-10RA, interleukin-10 receptor subunit alpha.

Table 2. Monogenic Inflammatory Bowel Disease

Table 3. IBD Phenotype in Monogenic versus Non-Monogenic Disease

Values are presented as mean±SD or number (%). Comparisons include only patients who underwent genetic testing (5 monogenic IBD; 20 non-monogenic IBD without pathogenic variants).

IBD, inflammatory bowel disease; PUCAI, Pediatric Ulcerative Colitis Activity Index; PCDAI, Pediatric Crohn’s Disease Activity Index; IBD-U, unclassified IBD; SD, standard deviation.

Table 4. Comparison of Treatments between Monogenic and Non-Monogenic Diseases

Values are presented as number (%).

Patients may have received multiple biological agents.

5-ASA, 5-aminosalicylic acid; 6-MP, 6-mercaptopurine; HSCT, hematopoietic stem cell transplantation; TNF, tumor necrosis factor.